FDA rejects wider use for J/Bayer’s Xarelto

<p>WASHINGTON (Reuters) – <span>Johnson Johnson</span> pronounced on Thursday that U.S. regulators have declined to approve a new use for a Xarelto blood clot preventer to revoke a risk of <span>heart attacks</span> and <span>strokes</span> in patients with <span>acute coronary syndrome</span>.</p>
<p> Patients with a condition, referred to as ACS, have had heart attacks or chest heedfulness that prove a risk of a heart attack. Their condition is customarily caused by blocked <span>coronary arteries</span> and an estimated 1 million people a year in a United States are hospitalized after carrying an ACS episode.</p>
<p> A row of outward medical experts to a <span>U.S. Food and Drug Administration</span> final month endorsed opposite capitulation of Xarelto for a new indication. The row pronounced a tablet looked promising, though voiced regard about blank cli...